Abbott Recalls affecting approximately three million FreeStyle Libre 3 continuous glucose monitoring sensors have been initiated by Abbott Laboratories in the United States following internal testing that revealed potentially life-threatening inaccuracies. The medical device leader announced this urgent correction on November 24, 2025, after determining that certain sensors from a single production line may provide incorrect low glucose readings that could lead to dangerous treatment decisions for people with diabetes.
The correction affects about 3 million sensors, with approximately half estimated to have already expired or been used . This represents one of the most significant medical device safety actions in the diabetes technology sector this year, highlighting ongoing challenges in ensuring the accuracy of devices that millions of patients depend on for daily health management.
Abbott Recalls Address Production Line Defect and Global Safety Concern
Abbott has received reports of 736 severe adverse events globally and seven deaths associated with the sensor malfunction , though none of the fatalities occurred in the United States. The severity of these incidents has prompted the company to take immediate corrective action and implement free replacement programs across multiple countries.
The problem stems from a manufacturing issue related to one production line among several that produce Libre 3 and Libre 3 Plus sensors . Abbott has emphasized that it identified and resolved the root cause of the defect, enabling continued production without anticipated supply disruptions. The initiative demonstrates the company’s commitment to patient safety, though questions remain about how the defective sensors reached consumers in the first place.
False Readings Create Critical Health Risks
Inaccurate low glucose readings pose serious dangers for diabetes patients who rely on continuous glucose monitors to make treatment decisions. False low readings could prompt users to consume unnecessary carbohydrates or skip insulin doses, potentially causing serious health complications including injury or death . For the estimated 114,000 Abbott employees globally and the company’s reputation as a diabetes technology leader, this recall presents significant operational and reputational challenges.
The FreeStyle Libre 3, which received FDA clearance in May 2022 , represents Abbott’s latest-generation CGM technology and has been marketed as a breakthrough in diabetes management. The device’s small sensor size and real-time glucose tracking capabilities have made it popular among patients seeking convenient monitoring solutions.
Comprehensive Replacement Program Launched
Abbott has established a dedicated website, FreeStyleCheck.com, where consumers can verify whether their sensors are affected by entering serial numbers. The company will replace any potentially affected sensors at no charge, and customer service representatives are available seven days a week from 8 a.m. to 8 p.m. Eastern Time, with 24/7 live chat support also accessible.
Consumers currently wearing or possessing potentially impacted sensors should immediately discontinue use and dispose of them . The Abbott Recalls guidance recommends using blood glucose meters or the built-in meter in FreeStyle Libre 3 readers when sensor readings don’t align with symptoms or expectations. This cautious approach underscores the seriousness of the safety concern.
Market Impact and Industry Implications
The correction extends beyond U.S. borders, with Abbott issuing this medical device correction in other affected countries where Libre 3 and Libre 3 Plus sensors are distributed . This global scope reflects the widespread adoption of Abbott’s glucose monitoring technology and the company’s international market presence serving two billion patients annually worldwide .
Importantly, FreeStyle Libre 3 readers and mobile apps are not impacted, and no other Libre products including FreeStyle Libre 14 day, FreeStyle Libre 2, FreeStyle Libre 2 Plus, or FreeStyle Libre Pro sensors are affected . This targeted nature of the action helps contain the potential market disruption while focusing remediation efforts on the specific problematic batch.
Abbott’s Response and Future Outlook
Abbott said it continues producing sensors to fulfill replacement and new orders and expects no significant supply disruptions. The company’s swift action in identifying the manufacturing defect and implementing corrective measures demonstrates operational maturity in handling product safety issues, though the incident will likely prompt increased scrutiny of quality control processes across the diabetes technology industry.
For Abbott, which has recently made headlines with its $21 billion acquisition announcement of Exact Sciences on November 20, 2025 , this recall presents a challenging juxtaposition of growth ambitions and operational challenges. The company’s ability to manage this safety issue while pursuing strategic expansion will be closely watched by investors and healthcare stakeholders.
The initiative also raises broader questions about continuous glucose monitor reliability and the regulatory oversight of diabetes technology devices. As more patients transition from traditional finger-stick testing to continuous monitoring systems, ensuring device accuracy becomes increasingly critical to preventing adverse health outcomes.
